Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Common Equity (2023 - 2025)

Compass Therapeutics' Common Equity history spans 3 years, with the latest figure at $196.8 million for Q4 2025.

  • For Q4 2025, Common Equity rose 57.14% year-over-year to $196.8 million; the TTM value through Dec 2025 reached $196.8 million, up 57.14%, while the annual FY2025 figure was $196.8 million, 57.14% up from the prior year.
  • Common Equity for Q4 2025 was $196.8 million at Compass Therapeutics, down from $209.6 million in the prior quarter.
  • Across five years, Common Equity topped out at $209.6 million in Q3 2025 and bottomed at $93.2 million in Q2 2025.
  • The 3-year median for Common Equity is $152.8 million (2023), against an average of $152.4 million.
  • The largest YoY upside for Common Equity was 57.14% in 2025 against a maximum downside of 36.21% in 2025.
  • A 3-year view of Common Equity shows it stood at $148.5 million in 2023, then dropped by 15.69% to $125.2 million in 2024, then soared by 57.14% to $196.8 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Common Equity are $196.8 million (Q4 2025), $209.6 million (Q3 2025), and $93.2 million (Q2 2025).